Literature DB >> 1116678

Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism.

R D Adler, L J Bennion, W C Duane, S M Grundy.   

Abstract

To better define the mechanisms by which chenodeoxycholic acid (CDCA) alters the lipid composition of bile and promotes dissolution of cholesterol gallstones, we have studied the effects of relatively low doses of CDCA on the metabolism of biliary lipids in 10 subjects without gallstones. In 5 subjects, the effects of CDCA feeding were compared to those of cholic acid, a bile acid that apparently does not dissolve cholesterol stones. The following measurements were carried out during control and treatment periods: (1) composition of biliary lipids, (2) hepatic secretion rates of biliary lipids, (3) pool sizes of bile acids, and (4) specific composition of bile acids. Low doses of CDCA consistently reduced the lithogenicity of gallbladder bile by decreasing the proportion of cholesterol relative to the solubilizing lipids--bile acids and lecithin. This decrease in lithogenicity was associated with a selective reduction in hepatic secretion rates of cholesterol. At the doses of CDCA given, secretion rates of bile acids and lecithin and pool sizes of bile acids were not significantly changed; also conversion of cholesterol into bile acids was not completely inhibited. Cholic acid feeding appeared to increase the total size of the bile acid pool, but it did not affect the lithogenicity of bile or secretion rates of cholesterol. The data show that at low doses CDCA lowers lithogenicity of bile by reducing hepatic secretion of cholesterol, while cholic acid does not have a similar effect.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116678

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Nuclear receptors CAR and PXR in the regulation of hepatic metabolism.

Authors:  E S Tien; M Negishi
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

2.  Postprandial serum bile acids in healthy man. Evidence for differences in absorptive pattern between individual bile acids.

Authors:  B Angelin; I Björkhem
Journal:  Gut       Date:  1977-08       Impact factor: 23.059

3.  The effect of wheat bran upon bile salt metabolism and upon the lipid composition of bile in gallstone patients.

Authors:  E W Pomare; K W Heaton; T S Low-Beer; H J Espiner
Journal:  Am J Dig Dis       Date:  1976-07

4.  Chenodeoxycholic acid induced liver injury in pregnant and neonatal baboons.

Authors:  C K McSherry; K P Morrissey; R L Swarm; P S May; W H Niemann; F Glenn
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

5.  Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.

Authors:  J H Iser; P N Maton; G M Murphy; R H Dowling
Journal:  Br Med J       Date:  1978-06-10

6.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

7.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

8.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible?

Authors:  J H Iser; G M Murphy; R H Dowling
Journal:  Gut       Date:  1977-01       Impact factor: 23.059

10.  Effect of bile acid feeding on hepatic steroid 12 alpha-hydroxylase activity in hamsters.

Authors:  S Kuroki; T Hoshita
Journal:  Lipids       Date:  1983-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.